METHODS

Subjects
For the study of human airway smooth muscle cells (HASMCs) in culture, healthy control subjects and subjects with COPD or asthma were recruited from respiratory clinics and underwent bronchoscopy.
COPD subjects were all ex or current smokers with spirometric evidence of airflow obstruction according to the Global Obstructive Lung Disease (GOLD) criteria for COPD 1 . Subjects with a history of asthma had a <10 pack year smoking history and met a diagnosis for asthma as described previously 2 . Control subjects included those with and without a smoking history without airflow obstruction.
To study tissue by immunohistochemistry, we used two sources of tissue; i) airway tissue collected at the time of lung resection from lung cancer patients who also met the GOLD criteria for COPD. Control tissue was also collected from subjects undergoing lung resection without evidence of COPD; ii) bronchial biopsies from healthy volunteers and asthmatic patients as described for HASMC cell culture 2, 3 . All subjects gave written informed consent, and the collection of tissue was approved by the National Research Ethics Service (reference numbers: 07/MRE08/42, 04/Q2502/74, 08/H0406/189). All methods were performed in accordance with the relevant guidelines and regulations.
Human airway smooth muscle cell (HASMC) isolation and culture
Subjects underwent bronchoscopy, and mucosal biopsies were collected for HASMC culture as described previously 3 . Pure human airway smooth muscle (ASM) bundles in airways isolated from lung resection and bronchial biopsy tissue were dissected free of surrounding tissue. The ASM bundles were cultured in DMEM supplemented with 10% FCS, 4 mM L-glutamine, 100 U/ml penicillin, 100mg/ml streptomycin, and 0.25μg/ml amphotericin. HASMC characteristics were determined by immunofluorescence with antibodies to α-smooth muscle actin (αSMA) (FITC directly conjugated) and myosin indirectly labelled with FITC 3 .
Immunohistochemistry
Bronchial tissue remote from the cancer was dissected from the lung resection material and embedded in glycol-methacrylate (GMA) and stored at −20°C as described previously 4 . Bronchial biopsies taken at bronchoscopy were also embedded in GMA as described previously 4 . GMA sections of 2 μm thickness were immunostained for Tensin1 (SAB4200283, 2.5 μg/ml, Sigma-Aldrich and sc-28542, 1 μg/ml, Santa-Cruz) or the appropriate isotype control at the same concentration as the primary antibody (X0936, 2.5 µg/ml, Dako) using the Dako EnVsion FLEX+ staining technique.
Sections were counter-stained using Mayer's haematoxylin and visualized using a light microscope.
The tensin1 antibodies were validated further using immunoprecipitation and siRNA downregulation (see below).
Images were collected and tensin1 immunostaining was quantified using Cell F software version 5.0 (Olympus). The thresholding technique was used to quantify tensin1 immunostaining based on the hue saturation and intensity (HSI) value 2 .
Quantitative Real Time PCR
HASMC and HBEC RNAs were isolated using the RNeasy Plus Kit (Qiagen, Manchester, UK) according to manufacturer's instructions. Detection of TNS1 mRNA was performed using the Fast SYBR Green Master Mix (Applied Biosystems, Paisley, UK) (TNS1 (forward primer: 5'-AGCGGAGACCTGACATCAC-3', reverse primers: 5'-CGGTTTCCCTTGTTGTGTAGAAC-3') and αSMA (forward primer: 5'-GAAGGAATAGCCACGCTCAG-3', reverse primer 5'-TTCAATGTCCCAGCCATGTA-3')), alongside primers targeting the internal normalized gene β-actin (Hs_ACTB_1_SG Quantitect Primer Assay, QT00095431; Qiagen). PCR products were run on an agarose gel to confirm the product amplified was the correct size, and were also sequenced. Tensin1 and αSMA mRNA expression was quantified using the ΔCT method 5 .
Cells were stimulated with 10 ng/ml transforming growth factor-β1 (TGFβ1) (R&D systems), cells were grown to confluence and then serum-starved for 24 hours prior to stimulation for a further
Western blotting
Tensin1 expression in primary HASMCs was analysed by western blotting as described previously 6 .
HASMCs were disrupted in lysis buffer and soluble protein from equivalent number of cells was resolved by 7.5% SDS-page and then transferred to a polyvinylidene (PVDF) membrane. The membrane was blocked using 5% Milk +0.1% TBS Tween20 and incubated with antibodies to Tensin1 (SAB4200283, 1 μg/ml, Sigma-Aldrich) and β-actin (sc-47778, 0.04 μg/ml Santa-Cruz) and αSMA (M0851, 1µg/ml, Dako). Secondary antibodies conjugated to horseradish peroxidase (HRP) were then applied (goat anti-rabbit HRP [sc-2054, 0.08 μg/ml, Santa-Cruz] or goat anti-mouse HRP [P0447, 0.5 μg/ml, Dako]). Immunolabelled proteins were visualized by chemiluminescence using ECL substrate and the ImageQuant LA S 4000 (GE Healthcare Life Sciences, Little Chalfont, UK). Band intensity was quantified using ImageJ software (National Institutes of Health; http://rsbweb.nih.gov/ij/).
Immunoprecipitation
HASMCs were disrupted in lysis buffer and as a pre-clearing step incubated with Protein A/G beads (sc-2003, Santa-Cruz) for 30 minutes at 4°C. Separately Protein A/G beads were incubated with either anti-tensin1 antibody (SAB4200283, 4 µg/ml, Sigma-Aldrich or sc-28542, 2 µg/ml, Santa-Cruz) or isotype control rabbit IgG (X0936, 4 µg/ml, Dako) for 30 minutes at 4°C. Pre-cleared lysates were then incubated with bead-antibody complexes for 16 hours at 4°C. Immunoprecipitated complexes were washed three times in lysis buffer and once in PBS, eluted in Laemmli buffer and denatured for 5 minutes at 95°C. Western blot analysis was then performed. Immunoprecipitates were probed with two anti-tensin1 antibodies (Sigma-Aldrich (SAB4200283, 1 µg/ml) and Santa-Cruz (sc-28542, 4 µg/ml)) and anti-αSMA (M0851, 1µg/ml, Dako) to examine tensin1 antibody specificity and the tensin1-αSMA interaction respectively.
Immunofluorescence
HASMCs were seeded into 8-well chamber slides, grown to confluence, and immunostained using mouse monoclonal αSMA (0.7 µg/ml, Dako) and isotype control FITC-conjugated mouse IgG2a (X0933, 10 µg/ml, Dako, Ely, UK), anti-Tensin1 antibody (4.5µg/ml, Sigma-Aldrich) and isotype control rabbit IgG (4.5µg/ml, Dako). Secondary antibodies labelled with AlexaFluor594 (A-11012, ThermoFisher) or FITC (FO382, Sigma-Aldrich) were applied and the cells were counterstained with 4', 6-diamidino-2-phenylindole (DAPI) (32670, Sigma-Aldrich). To study the effect of the extracellular matrix protein fibronectin and TGFβ1 on tensin1 expression, slides were coated with human recombinant fibronectin (F0895, Sigma-Aldrich) for 1 hour prior seeding and stimulated with TGFβ1 
Human airway smooth muscle cell transfection with siRNA
HASMCs were transfected with siRNA smartpools directed against tensin1 (M-009976-00, Dharmacon) and a non-targeting siCONTROL (D-001206-14, Dharmacon). HASMCs were plated in culture media in the absence of antibiotics in a 6 well plate and incubated at 37°C, 5% CO2 overnight. 5 μl of Lipofectamine 2000 (11668, Invitrogen) was diluted in 105 μl serum and antibiotic-free media and incubated for 5 minutes before adding to siRNA diluted in 105 μl of serum and antibiotic-free media. The mixture was incubated for 20 minutes and added to cells with an additional 1.78 ml culture media. The cells were incubated with the complexes for 5 hours. After 5 hours, medium was replaced with antibiotic-free media for 48 hours 7 .
Survival/Proliferation assay
The MTS assay (G3582, Promega) was used to assess survival and proliferation of the cells after tensin1 silencing. 48 hours after transfection, cells were collected and 2 x 10 3 cells were plated into 96-well plates in culture media in the absence of antibiotics overnight. Cells were stimulated with TGFβ1 for 24 hours. 20 μl of MTS solution was added to each well. Plates were then incubated at 37°C for 4 hours. The optical density (OD) at 490nm was determined with a spectrophotometer. Each experimental condition was run in triplicate.
TGFβ1 ELISA
Tensin1 knockdown was performed as described above and supernatants were collected. A commercial ELISA was used to measure TGFβ1 in tensin1 knockdown sample supernatants according to the manufacturer's protocol (DY240, R&D systems). The lower limit of TGFβ1 detection was 0.031 pg/ml and the upper limit was 2 pg/ml. Assay samples were diluted and activated before ELISA. Each experimental condition was run in triplicate.
Collagen gel contraction assay
Tensin1 knockdown was performed as above and then cells were detached and embedded in collagen gels as described previously 8 . Bradykinin was then added to appropriate wells to a final concentration of 1nM (B3259, Sigma-Aldrich). Photographs were taken at 0, 4, 18, 24 and 48 hours. (GraphPad Software, Inc., La Jolla, CA, USA). P < 0.05 was taken as statistically significant. Gels containing siRNA SMARTpool (sihT1) HASMCs showed a greatly reduced ability to contract, with signiJicant differences compared to controls at 18 , 24 and 48 hours. Figure S4 . The effect of bradykinin on HASMC collagen gel contraction. Cells were transfected with siRNA directed against tensin1 and incubated within 3D collagen gels. The extent of spontaneous collagen gel contraction was recorded at 1,2,3, 4, 18, 24 and 48 hours. QuantiJication of collagen gel contraction using gel area measurement was performed (n=8, Mean±SEM). Data shown are pooled COPD (n=4) and healthy donors (n=4) which did not differ. HASMCs transfected with tensin1 siRNA SMARTpool showed a greatly reduced ability to contract, with signiJicant differences compared to controls at 24 (**p=0.0052) and 48 hours (****p<0.0001). The extent of collagen gel contraction following bradykinin stimulation was signiJicantly increased, with signiJicant differences at 18 (nontransfected (*p=0.0187), mock (*p=0.0102) and siCON (**p=0.0020)) , 24 (nontransfected (**p=0.0023), mock (**p=0.0016) and siCON (***p=0.0001)) and 48 hours (non-transfected (****p<0.0001), mock (****p<0.0001) and siCON (****p<0.0001)). Tensin1-depleted HASMCs did not respond signiJicantly to bradykinin, when compared to spontaneous contraction. Data analysed using twoway ANOVA with Dunnett's comparison test. Figure S5 . Overexpressing tensin1 has no effect on prolifera9on. (A) Sequencing data confirming inser5on of muta5on at 4422 bp and therefore genera5on of the pEGFP construct containing tensin1 (-CC-) used to validate the RFLP method and transfect HASMCs. (B) AJer tensin1 overexpression with pEGFP constructs containing full length of TNS1 cDNA with either the C or T allele was achieved, cell survival and prolifera5on was assessed using the MTS assay. Data were compared using one-way ANOVA with DunneT's mul5ple comparison test. Overexpression of tensin1 using pEGFP constructs did not have any effect on HASMC survival when compared to the controls. Data shown are pooled from COPD (n=4) and healthy donors (n=4) which did not differ 
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